A5022522550- Hormonal and reproductive studies
- Sexual function and dysfunction studies
- Pharmacology and Obesity Treatment
- Sexual Differentiation and Disorders
- Urinary Bladder and Prostate Research
- Muscle metabolism and nutrition
- Prostate Cancer Treatment and Research
- Pharmacological Effects and Assays
- Sexuality, Behavior, and Technology
- Hypothalamic control of reproductive hormones
- Genital Health and Disease
- Crystallization and Solubility Studies
- X-ray Diffraction in Crystallography
- Doping in Sports
- Urologic and reproductive health conditions
- Catalytic C–H Functionalization Methods
- Stress Responses and Cortisol
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Hormonal Regulation and Hypertension
- Ovarian function and disorders
- Catalytic Cross-Coupling Reactions
- Adrenal Hormones and Disorders
- Chemical Reactions and Mechanisms
- Testicular diseases and treatments
- SARS-CoV-2 and COVID-19 Research
Dresden International University
2015-2025
Hamad Medical Corporation
2018-2024
Cornell University
2023-2024
Weill Cornell Medical College in Qatar
2020-2023
Hamad General Hospital
2018
Gulf Medical University
2006-2017
Segeberger Kliniken
2006-2016
Klinik und Poliklinik für Urologie
2014
Boston University
2014
Hamburg Institut (Germany)
2010
Type 2 diabetes (T2D) is a public health threat. Prediabetes represents window of opportunity for intervention to prevent T2D. Men with T2D and prediabetes often have low testosterone. Since testosterone improves glycemic control in T2D, we investigated whether therapy (TTh) men hypogonadism prevents progression T2D.Three hundred sixteen (defined as HbA1c 5.7-6.4%) total levels ≤12.1 nmol/L combined symptoms were analyzed. Two twenty-nine received parenteral undecanoate (T-group), 87 served...
Long-term testosterone replacement therapy (TRT) up to 5 years has been shown produce progressive and sustainable weight loss (WL) in hypogonadal men. This study investigated effects of long-term TRT 8 men with different obesity classes. From two independent observational registries we identified a total 411 obese, receiving urological clinics. The on anthropometric as well metabolic parameters were studied for maximum duration years, mean follow-up: 6 years. All received long-acting...
To investigate effects of long-term testosterone (T) therapy in obese men with T deficiency (TD) and type 2 diabetes mellitus (T2DM), data were collected from two observational, prospective, cumulative registry studies 561 TD receiving for up to 6 years. A subgroup hypogonadal T2DM was analyzed. Weight, height, waist circumference (WC), fasting blood glucose (FBG), glycated haemoglobin (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"...
Whether testosterone replacement therapy (TRT) is a lifelong treatment for men with hypogonadism remains unknown. We investigated long-term TRT and withdrawal on obesity prostate-related parameters. Two hundred sixty-two hypogonadal patients (mean age 59.5) received undecanoate in 12-week intervals maximum of 11 years. One forty-seven had interrupted mean 16.9 months resumed thereafter (Group A). The remaining 115 were treated continuously B). Prostate volume, prostate-specific antigen...
Abstract Testosterone plays a pivotal role in male health throughout the lifespan. Men generally exhibit higher serum testosterone levels than women, influencing critical aspects of physiology. It drives normal sexual differentiation during fetal development, promotes acquisition pubertal traits, and induces development secondary sex characteristics. While naturally decline with age, this decrease varies greatly between individuals, indicating that aging alone does not account for any...
The objective of this study was to observe the dose-response effects testosterone (T) treatment on symptoms sexual dysfunction and metabolic syndrome. Two cohorts elderly men with late-onset hypogonadism were followed over 9 months. Group 1, consisting 28 (mean age, 61 years; mean T level, 2.07 +/- 0.50 ng/mL), received long-acting undecanoate (TU; 1000 mg); group 2, composed 27 60 2.24 0.41 gel (50 mg/day) for In patients treated gel, plasma levels rose from 2.95 0.52 (statistically...
Introduction and objective. Androgen deprivation therapy of prostate cancer with luteinizing hormone releasing agonists may result in loss bone mass, changes body composition a deterioration arterial stiffness. The present study monitored the effects androgen men insulin-dependent diabetes on glycaemic control biochemical cardiovascular risk markers.Methods. Twenty-nine patients from urology practice were included. All had mellitus prior to being diagnosed metastatic cancer. In retrospective...
Hypogonadism is associated with increased fat mass and reduced muscle mass, which contributes to obesity health risks, such as cardiovascular disease.Testosterone treatment of hypogonadal men improves reduces mass; however, many these studies are short duration.Thus, the long-term effects testosterone on body anthropometry not known.Long-term men, up 5 years duration, produced marked significant decrease in weight, waist circumference index. adiposity. Testosterone ameliorates loss...
Although there is no evidence that testosterone therapy increases the risk of prostate cancer, a paucity long-term data. We determined whether incidence cancer increased in hypogonadal men receiving therapy.In 3 parallel, prospective, ongoing, cumulative registry studies 1,023 received therapy. Two study cohorts were treated by urologists (since 2004) and 1 was at an academic andrology center 1996). Patients when total 12.1 nmol/l or less (350 ng/dl) symptoms hypogonadism present. Maximum...
The effects of administration testosterone (T) gel, resulting in plasma T levels the low range reference values, followed by undecanoate (TU), producing mid-normal range, were measured 27 hypogonadal men aged 47–74 years. gel had positive on International Index Erectile Function, Aging Males' Symptoms Scale and Prostate Score metabolic syndrome. improvement was larger when TU administered higher. reduction waist circumference cholesterol with than while increases high-density lipoprotein sex...
Administration of testosterone undecanoate (TU) over 12 months to men with sexual dysfunction and signs the metabolic syndrome, restored their plasma (T) levels mid-range reference values. This had a beneficial effect on functioning as evidenced by an improvement scores International Index Erectile Function. The Aging Male Symptoms score, AMS, were also improved. Most impressive improvements in parameters syndrome; they all improved appeared largely correlated (i.e., decline waist...
Until a decade ago the ailments of elderly men, such as atherosclerosis, hypertension, diabetes mellitus, lower urinary tract symptoms and erectile dysfunction (ED), were regarded distinct diagnostic/therapeutic entities but there is growing awareness that these are not disparate and, to improve health ageing male, require an integral approach. There inter-dependence between metabolic syndrome, ED patterns testosterone in men. The main features syndrome abdominal obesity, insulin resistance,...
Long-term testosterone therapy (TTh) in men with hypogonadism has been shown to improve all components of the metabolic syndrome. In this study, we investigated effects long-term TTh up 8 years hypogonadal a history cardiovascular disease (CVD).In two urological clinics observational registries, identified 77 receiving who also had CVD. The on anthropometric and parameters were for maximum duration years. Any occurrence major adverse events was reported. All received long-acting injections...
Intervention with Testosterone treatment for up to 18 years, in a prospective data collection shows that long-term testosterone has significant reduction mortality [1-3] and increase of hematocrit, which theoretically could risk cardiovascular events, not be proven [4]. Summarizing results research aimed throw the light on relationship between hematocrit all-cause men receiving therapy setting [5,6].